Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus
- 10 October 2007
- journal article
- review article
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 59 (12) , 1242-1262
- https://doi.org/10.1016/j.addr.2007.04.016
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Molecular Mechanism of a Thumb Domain Hepatitis C Virus Nonnucleoside RNA-Dependent RNA Polymerase InhibitorAntimicrobial Agents and Chemotherapy, 2006
- Ribavirin Antagonizes the In Vitro Anti-Hepatitis C Virus Activity of 2′- C -Methylcytidine, the Active Component of ValopicitabineAntimicrobial Agents and Chemotherapy, 2006
- Non-nucleoside Inhibitors Binding to Hepatitis C Virus NS5B Polymerase Reveal a Novel Mechanism of InhibitionJournal of Molecular Biology, 2006
- Novel Inhibitors of Hepatitis C Virus RNA-dependent RNA PolymerasesJournal of Molecular Biology, 2006
- Binding Site Characterization and Resistance to a Class of Non-nucleoside Inhibitors of the Hepatitis C Virus NS5B PolymeraseJournal of Biological Chemistry, 2005
- Evasion of intracellular host defence by hepatitis C virusNature, 2005
- On the size of the active site in proteases. I. PapainPublished by Elsevier ,2005
- NM 283, AN EFFICIENT PRODRUG OF THE POTENT ANTI-HCV AGENT 2′-C-METHYLCYTIDINENucleosides, Nucleotides and Nucleic Acids, 2005
- Solution structure and dynamics of the single-chain hepatitis C virus NS3 protease NS4A cofactor complexJournal of Molecular Biology, 2001
- The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanismJournal of Molecular Biology, 1999